Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors

Growth Factor ◽

Phase I ◽

Pharmacokinetic Study ◽

Phase I Trial ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.2522 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 2522-2522 ◽

Cited By ~ 1

Author(s):

Su Jin Lee ◽

Jun Soo Ham ◽

Hee Kyung Kim ◽

Seonggyu Byeon ◽

Seon Young Lee ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Phase I ◽

Pharmacokinetic Study ◽

Phase I Trial ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors

Annals of Oncology ◽

10.1093/annonc/mdv144 ◽

2015 ◽

Vol 26 (6) ◽

pp. 1230-1237 ◽

Cited By ~ 42

Author(s):

E.G. Chiorean ◽

H.I. Hurwitz ◽

R.B. Cohen ◽

J.D. Schwartz ◽

R.P. Dalal ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Advanced Solid Tumors ◽

Tanibirumab (TTAC-0001): A fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2)

Archives of Pharmacal Research ◽

10.1007/s12272-011-0821-9 ◽

2011 ◽

Vol 34 (8) ◽

pp. 1223-1226 ◽

Cited By ~ 15

Author(s):

Sang Hoon Lee

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2

Drug Design Development and Therapy ◽

10.2147/dddt.s150241 ◽

2018 ◽

Vol Volume 12 ◽

pp. 495-504 ◽

Cited By ~ 4

Author(s):

Weon Sup Lee ◽

Sang Ryeol Shim ◽

Seon Young Lee ◽

Jin San Yoo ◽

Sung Kweon Cho

Keyword(s):

Clinical Trial ◽

Monoclonal Antibody ◽

Growth Factor ◽

Phase I ◽

Interspecies Scaling ◽

Vascular Endothelial ◽

Preclinical Pharmacokinetics ◽

Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study

Investigational New Drugs ◽

10.1007/s10637-013-9998-8 ◽

2013 ◽

Vol 32 (2) ◽

pp. 303-311 ◽

Cited By ~ 15

Author(s):

Patricia M. LoRusso ◽

Smitha Krishnamurthi ◽

Hagop Youssoufian ◽

Nancy Hall ◽

Floyd Fox ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Phase 1 ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Phase 1 Study ◽

Solid Malignancies ◽

Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor

Cancer Science ◽

10.1111/cas.12034 ◽

2012 ◽

Vol 104 (1) ◽

pp. 98-104 ◽

Cited By ~ 12

Author(s):

Hidetoshi Hayashi ◽

Takayasu Kurata ◽

Yasuhito Fujisaka ◽

Hisato Kawakami ◽

Kaoru Tanaka ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Solid Tumor ◽

Phase I Trial ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

647 POSTER A phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(06)70652-8 ◽

2006 ◽

Vol 4 (12) ◽

pp. 195 ◽

Cited By ~ 1

Author(s):

R. Cohen ◽

D. Camidge ◽

S. Diab ◽

L. Gore ◽

L. Chow ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Phase I ◽

Dose Escalation ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Dose Escalation Study ◽

Igg1 Monoclonal Antibody ◽

406 POSTER IMC-18F1, a recombinant human monoclonal antibody (MAb) against the vascular endothelial growth factor receptor-1 (VEGFR-1), in the treatment of patients (pts) with advanced solid malignancies: A Phase 1 study

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(08)72340-1 ◽

2008 ◽

Vol 6 (12) ◽

pp. 127-128

Author(s):

S. Krishnamurthi ◽

P.H.B. Goncalves ◽

F. Fox ◽

N. Hall ◽

E. Rowinsky ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Phase 1 ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Phase 1 Study ◽

Solid Malignancies ◽

Intravitreal Tanibirumab, a Fully Human Monoclonal Antibody Against Vascular Endothelial Growth Factor Receptor 2, Partially Suppresses and Regresses Laser-Induced Choroidal Neovascularization in a Rat Model

Journal of Ocular Pharmacology and Therapeutics ◽

10.1089/jop.2014.0021 ◽

2014 ◽

Vol 30 (10) ◽

pp. 847-853 ◽

Cited By ~ 4

Author(s):

Jaeryung Kim ◽

Tae Eun Kim ◽

Ju-A Kim ◽

Ji-Hyun Yun ◽

Seongsoo Sohn ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Choroidal Neovascularization ◽

Rat Model ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma

Cancer ◽

10.1002/cncr.24213 ◽

2009 ◽

Vol 115 (10) ◽

pp. 2188-2198 ◽

Cited By ~ 51

Author(s):

David A. Reardon ◽

Merrill J. Egorin ◽

Annick Desjardins ◽

James J. Vredenburgh ◽

Jan H. Beumer ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Malignant Glioma ◽

Pharmacokinetic Study ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽